TLDR JAK inhibitors and combination therapies show promise for treating severe alopecia areata.
Alopecia areata (AA) is an autoimmune disorder causing localized hair loss, with CD8 + T cells implicated in its etiology. Corticosteroids are effective for mild to moderate cases, but severe forms like alopecia universalis are challenging to treat. JAK inhibitors, such as baricitinib, ritlecitinib, upadacitinib, and tofacitinib, show promise in promoting hair regrowth. Methotrexate and cyclosporine are effective, particularly in combination therapies, while minoxidil offers additional benefits. Tacrolimus needs further investigation. Understanding the mechanisms and effectiveness of these treatments is essential for improving outcomes and quality of life for those with AA.
40 citations
,
October 2012 in “Dermatologic clinics” More research is needed to understand the genetic causes of Alopecia areata to develop better treatments.
January 2024 in “International journal of homoeopathic sciences” Early intervention and patient education are crucial for managing alopecia areata.
191 citations
,
May 2018 in “British journal of dermatology/British journal of dermatology, Supplement” Alopecia areata is likely an autoimmune disease with unclear triggers, involving various immune cells and molecules, and currently has no cure.
Alopecia areata is an autoimmune disease affecting hair follicles and may harm heart health.
24 citations
,
January 2008 in “KARGER eBooks” The document concludes that ongoing research using animal models is crucial for better understanding and treating Alopecia Areata.
December 2016 in “Springer eBooks” A 45-year-old woman with autoimmune diseases experienced patchy hair loss due to alopecia areata, which has no cure but can be treated, with varying success.
